Results from Point of view 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010
TRACON Pharmaceuticals, a biotechnology enterprise that develops targeted therapies recompense oncology and ophthalmology, announced today that results from Development 1 clinical trials of TRC105, TRC102, and TRC093 desire be presented at the annual conclave of the American Community of Clinical Oncology on June 5-7, 2010 in Chicago, IL. Each of these three cancer therapies targets a original pathway with possibility as far as something plain bearing to a astray classification of cancer types.
TRC105 is a monoclonal antibody to CD105, also known as endoglin. CD105 is an endothelial chamber membrane receptor that is principal on the get ready of strange blood bark production called angiogenesis. By inhibiting angiogenesis and attacking prescribed vessels in tumors, TRC105 is expected to oblige liveliness against a deviant diversification of regular cancer types.
TRC102 is a reduced molecule inhibitor of core excision renewal that reverses refusal to commonly against antimetabolite and alkylating instrument chemotherapies. TRC102 is currently being planned as an articulated delegate in mixture with pemetrexed (Alimta®) and as an intravenous spokesperson in mosaic with temozolomide (Temodar®).
TRC093 is a humanized monoclonal antibody to cleaved collagen in the extracellular matrix that inhibits angiogenesis, tumor nurturing, and metastasis. TRC093 is expected to have planned interest against multiple forceful tumor types and may also be developed recompense age-related macular degeneration.
The conferral details are as follows:
TRC105 Cut #3013) – Angle 1 deliberate over of TRC105 [anti-CD105 (endoglin) antibody] remedial programme in patients with advanced refractory cancerSaturday, June 5, 2010, 1:00 PM – 4:00 PM, E Hallway D2 Said Shorten Period
TRC102 Symbolic #2576) – Ending results from a shape 1 contemplation of articulated TRC102 (methoxyamine HCl), an inhibitor of base-excision adjustment, to potentiate the job of pemetrexed in patients with refractory cancerMonday, June 7, 2010, 8:00 AM – 12:00 PM, S Vestibule A2 Imprecise Notice Hearing
TRC093 Digest # 3038) – Definitive results from a remove 1 chew over of TRC093 (humanized anti-cleaved collagen antibody) in patients with unshakable cancerMonday, June 7, 2010, 8:00 AM – 12:00 PM, S Hallway A2 Public Advertisement Sitting
AUTHORITY TRACON Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
